PDCD1 and neoplasm: Interestingly, combination therapy of both anti-PD-1 and anti-PS without DPX-R9F/CPA resulted in increased tumour growth similar to untreated groups, highlighting the benefit of DPX-R9F/CPA treatment in generating immune responses.